SohnX Hong Kong: Gabriel Grego of Quintessential Capital on why he’s short Cassava Sciences

HFA Padded
Michelle deBoer-Jones
Published on

The field of short-sellers has shrunk dramatically since the Department of Justice's probe was revealed earlier this year. However, some stalwart investors remain committed to the cause of unveiling potentially fraudulent companies.

Background On Cassava Sciences, Formerly Known As Pain Therapeutics

At the SohnX Hong Kong Conference, reputable short-seller Gabriel Grego of Quintessential Capital Management unmasked the individuals behind Cassava Sciences, previously known as Pain Therapeutics. He also explained why he sees problems at the company that has caused him to flag it as potentially fraudulent.

Q2 2022 hedge fund letters, conferences and more

This article is only available for Premium Members
Subscribe today and get :
Insider Strategies and Letters to Shareholders from the Top Hedge Funds
Exclusive Access to coverage of Private, Closed-Door Investor Conferences
Hedge Fund Manager Research Currently Producing 21% – 40% Returns Annually

Don’t have an account?

Subscribe now and get 7 days free!
HFA Padded

Michelle deBoer-Jones is editor-in-chief of Hedge Fund Alpha. She also writes comparative analyses of stocks for TipRanks and runs Providence Writing Services. Previously, she was a television news producer for eight years, producing the morning news programs for NBC affiliates in Evansville, Indiana and Huntsville, Alabama and spending a short time at the CBS affiliate in Huntsville.